Speaker(s): 

Richard "Hal" Flowers, MD - Outside Speaker from UVA Health in Charlottesville, VA - Disclosures: has served as a principal investigator for Abbvie, Acelyrin, AstraZeneca, Clinuvel, Regeneron/Sanofi and Sun Pharmaceuticals. Has served on advisory boards for Argenx, Bristol-Myers Squibb, Incyte, Janssen, and Priovant.

Moderator(s):   

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Identify key clinical, histopathologic, and immunofluorescence findings that distinguish major immunobullous diseases
• Formulate evidence-based treatment strategies incorporating conventional and emerging therapies for immunobullous disorders
• Identify uncommon and diagnostically challenging complex medical dermatology conditions
• Formulate practical management plans for complex dermatologic disease, including escalation and multidisciplinary care

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Eric Hossler, MD and Ashley Hubal, PA-C have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose: Natalie Stinton, DMD, Kelly Ryan Shaw, PsyD, Rebecca Stoudt, DNP, PhD, CRNA, Angela Slampak-Cindric, PharmD, BCPS

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session:

None